News

Combination regimen will likely change standard of care for resected pancreatic cancer

Publish date: June 4, 2016

 

AT The 2016 ASCO ANNUAL Meeting

References

Dr. Neoptolemos disclosed that he receives grant and research support from Taiho Pharmaceutical, Kael-Gemvax, AstraZeneca, Clovis Oncology, Ventana, and Merck, and that he receives educational travel grants from NuCana BioMed.

Pages

Recommended Reading

VIDEO: Asymptomatic pancreatic cysts rarely became malignant
MDedge Hematology and Oncology
Colorectal cancer threatens younger people
MDedge Hematology and Oncology
Race predicts poor outcomes in people with liver cancer
MDedge Hematology and Oncology
Fecal bacteria plus FIT promising in diagnosis of colorectal cancer
MDedge Hematology and Oncology
Metabolic factors associated with pancreatic NETs
MDedge Hematology and Oncology
Methylated DNA markers hold promise for Lynch syndrome
MDedge Hematology and Oncology
Sponge-on-a-string could move Barrett’s screening from GI lab to primary care
MDedge Hematology and Oncology
Novel drug shows preclinical success in pancreatic cancer
MDedge Hematology and Oncology
Histologic examination of anastomotic stapler doughnuts may not yield clinical benefit
MDedge Hematology and Oncology
Statins, but not aspirin, linked to lower pancreatic cancer risk
MDedge Hematology and Oncology